About Encycle Therapeutics
Encycle Therapeutics is a company based in Toronto (Canada) founded in 2012 was acquired by Zealand Pharma in October 2019.. Encycle Therapeutics has raised $5.62 million across 3 funding rounds from investors including Zealand Pharma, Takeda Ventures and Accel-Rx. Encycle Therapeutics offers products and services including Supplement Reviews and Product Analysis. Encycle Therapeutics operates in a competitive market with competitors including Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Toronto, Canada
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$5.62 M (USD)
in 3 rounds
-
Latest Funding Round
$2.28 M (USD), Series A
Sep 30, 2015
-
Investors
Zealand Pharma
& 6 more
-
Employee Count
Employee Count
-
Acquired by
Zealand Pharma
(Oct 22, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Encycle Therapeutics
Encycle Therapeutics offers a comprehensive portfolio of products and services, including Supplement Reviews and Product Analysis. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for evaluating dietary supplements like Lipozem
Expert reviews on joint and weight loss supplements
Funding Insights of Encycle Therapeutics
Encycle Therapeutics has successfully raised a total of $5.62M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $2.28 million completed in September 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $2.3M
-
First Round
First Round
(18 Jun 2012)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2015 | Amount | Series A - Encycle Therapeutics | Valuation | Takeda Ventures | |
| Nov, 2014 | Amount | Series A - Encycle Therapeutics | Valuation |
investors |
|
| Jun, 2012 | Amount | Seed - Encycle Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Encycle Therapeutics
Encycle Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Zealand Pharma, Takeda Ventures and Accel-Rx. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Early-stage technology startups are supported through investments by MaRS IAF.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Encycle Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Encycle Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Encycle Therapeutics Comparisons
Competitors of Encycle Therapeutics
Encycle Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Septerna, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| domain | founded_year | HQ Location |
CRAC channel inhibitors are developed for inflammatory diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Encycle Therapeutics
When was Encycle Therapeutics founded?
Encycle Therapeutics was founded in 2012.
Where is Encycle Therapeutics located?
Encycle Therapeutics is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Is Encycle Therapeutics a funded company?
Encycle Therapeutics is a funded company, having raised a total of $5.62M across 3 funding rounds to date. The company's 1st funding round was a Seed of $840K, raised on Jun 18, 2012.
What does Encycle Therapeutics do?
Encycle Therapeutics is a drug discovery company that is exploiting a novel synthetic method to generate nacellins, more drug-like cyclic peptides. It has generated several scaffolds that are membrane permeable and orally bioavailable, such nacellins being ideal for targeting protein-protein interactions. Its current programs focus on the development of nacellins to treat inflammatory bowel disease and fibrosis. Its lead program aims to develop orally bioavailable inhibitors of integrin α4β7 for the treatment of ulcerative colitis, Crohns disease, and other conditions. Has also entered into several ongoing research collaborations with major pharmaceutical companies, including AstraZeneca, GSK, Merck, Pfizer and Takeda.
Who are the top competitors of Encycle Therapeutics?
Encycle Therapeutics's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
What products or services does Encycle Therapeutics offer?
Encycle Therapeutics offers Supplement Reviews and Product Analysis.
Who are Encycle Therapeutics's investors?
Encycle Therapeutics has 7 investors. Key investors include Zealand Pharma, Takeda Ventures, Accel-Rx, BDC Capital, and MaRS IAF.